ORIC Stock Summary and Trading Ideas (Oric Pharmaceuticals | NASDAQ:ORIC)

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Oric Pharmaceuticals trades on the NASDAQ stock market under the symbol ORIC.

As of April 10, 2026, ORIC stock price declined to $10.15 with 1,898,207 million shares trading.

ORIC has a beta of 0.55, meaning it tends to be less sensitive to market movements. ORIC has a correlation of 0.01 to the broad based SPY ETF.

ORIC has a market cap of $1.14 billion. This is considered a Small Cap stock.

In the last 3 years, ORIC traded as high as $16.65 and as low as $3.90.

The top ETF exchange traded funds that ORIC belongs to (by Net Assets): VTI, XBI, IWM, VXF, VTWO.

ORIC has outperformed the market in the last year with a return of +135.5%, while the SPY ETF gained +30.9%. In the last 3 month period, ORIC beat the market returning +10.9%, while SPY returned -1.8%. However, in the most recent 2 weeks ORIC has underperformed the stock market by returning -15.8%, while SPY returned +7.2%.

ORIC support price is $9.73 and resistance is $11.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ORIC shares will trade within this expected range on the day.